Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.140
-0.010 (-0.47%)
At close: Aug 1, 2025, 4:00 PM
2.120
-0.020 (-0.93%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.

The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals logo
CountryUnited States
Founded2002
IndustryBiotechnology
SectorHealthcare
Employees13
CEONadav Kidron

Contact Details

Address:
1185 Avenue of the Americas, Third Floor
New York, New York 10036
United States
Phone844 967 2633
Websiteoramed.com

Stock Details

Ticker SymbolORMP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001176309
CUSIP Number68403P203
ISIN NumberUS68403P2039
Employer ID98-0376008
SIC Code2834

Key Executives

NamePosition
Nadav Kidron Esq.President, Chief Executive Officer and Executive Chairman
Avraham GabayChief Financial Officer, Treasurer and Secretary
Joshua HexterChief Operating and Business Officer
Dr. Miriam Kidron Ph.D.Chief Scientific Officer and Director

Latest SEC Filings

DateTypeTitle
Jul 23, 20258-KCurrent Report
Jul 16, 2025ARSFiling
Jul 16, 2025DEF 14AOther definitive proxy statements
Jul 16, 202510-K/A[Amend] Annual report
May 21, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
Apr 28, 20258-KCurrent Report
Mar 27, 202510-KAnnual Report
Mar 3, 20258-KCurrent Report
Feb 27, 20258-KCurrent Report